Adynxx, Inc.

Equities

ADYX

US00784D1037

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:31:06 2023-12-05 am EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2019	Adynxx, Inc. announced that it has received $0.45 million in funding	CI
2019	Adynxx, Inc. announced a financing transaction	CI

Adynxx, Inc. announced that it has received $0.45 million in funding

December 16, 2019

On December 17, 2019, Adynxx, Inc. (OTCPK:ADYX) closed the transaction. The company raised its second tranche bringing the total gross proceeds raised in the transaction to $450,000. The transaction included participation from entities affiliated with Domain Associates LLC.

Latest news about Adynxx, Inc.

Adynxx, Inc. announced that it has received $0.45 million in funding	19-12-16	CI
Adynxx, Inc. announced a financing transaction	19-11-29	CI
Adynxx, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019	19-11-14	CI
Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic	19-10-02	CI
Adynxx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2019	19-08-14	CI
Adynxx, Inc. Announces Board Changes	19-07-22	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from S&P TMI Index	19-06-14	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from S&P TMI Index	19-06-14	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from NASDAQ Composite Index	19-06-12	CI
Adynxx, Inc. Announces Board Committee Appointments	19-05-31	CI
Adynxx, Inc. Announces Management Changes	19-05-09	CI
Adynxx, Inc.(OTCPK:ADYX) added to NASDAQ Composite Index	19-05-06	CI
Adynxx, Inc.(OTCPK:ADYX) added to S&P TMI Index	19-05-06	CI
Adynxx, Inc. completed the acquisition of Alliqua BioMedical, Inc. in a reverse merger transaction.	19-05-02	CI
Adynxx Provides Clinical Updates	19-04-22	CI
Adynxx, Inc. Announces Receipt of Notice of Award for $5.7 Million in Federal Grant Funding	18-12-13	CI
Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis	18-11-15	CI
Adynxx, Inc. entered into a definitive merger agreement to acquire Alliqua BioMedical, Inc. in a reverse merger transaction.	18-10-11	CI
Adynxx Completes Enrollment in ADYX-004, a Phase 2 Study of Brivoligide	17-10-04	CI
Adynxx, Inc. Initiates ADYX-004, a Phase 2 Study of AYX1, Lead Compound for the Treatment of Post-Surgical Pain	17-03-01	CI
Adynxx, Inc announced that it has received $16 million in funding from TPG Biotech, Domain Associates, L.L.C., and another investor	17-01-08	CI
Adynxx, Inc announced that it expects to receive $13.97 million in funding	16-12-19	CI
Adynxx Reports Positive Results for Phase 2b Study of AYX1	15-08-11	CI
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1	14-07-16	CI
Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of its Lead Product Candidate AYX1	13-09-05	CI

Chart Adynxx, Inc.

Duration

Period

More charts

Company Profile

Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADYNXX, INC.	-.--%	5
IQVIA HOLDINGS INC.	+1.14%	43.84B
MODERNA, INC.	+5.27%	41.68B
LONZA GROUP AG	+44.93%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+8.10%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.52%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.05%	12.29B
MEDPACE HOLDINGS, INC.	+25.60%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.95%	11.15B

Other Biotechnology & Medical Research